Royalty Pharma (NASDAQ:RPRX) Stock, Quote.Headers.trade-ideas

Royalty Pharma

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Biogen - logo

Biotech

Earnings

Large Cap

News

Guidance

Health Care

Financing

Contracts

Movers

General

BIIB

RPRX

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to $250 million in R&amp;D funding from Royalty Pharma.

Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&amp;D Funding Pact With Royalty Pharma

Wall street shutter3

Equities

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Federal Reserve

ETFs

$BTC

AAPL

ALSN

ARVN

BABA

Brighthouse Financial, Inc. - Common Stock

CARR

DASH

SPDR Dow Jones Industrial Average ETF Trust

GILD

INTC

IPGP

LCII

LDOS

MYTE

SPGI

STLD

TSLA

USAC

PowerShares DB US Dollar Index Bullish Fund

WELL

Select Sector SPDR-Consumer Discretionary

US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What&#39;s Driving Markets Tuesday?

CYTK

Analyst Color

Price Target

Initiation

Analyst Ratings

Trading Ideas

AMGN

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&amp;A and deals.

Cytokinetics Heart Drug&#39;s Future Sparks Optimism Despite M&amp;A Hurdles and Royalty Deal Concerns: Analyst

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma PLC

Press Releases

Royalty Pharma to Present at Upcoming Investor Conferences

Dividends

Royalty Pharma Announces Dividend Increase

Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference

Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds

Royalty Pharma Reports Q4 and Full Year 2024 Results

Royalty Pharma Announces R&D Funding Collaboration With Biogen

Royalty Pharma to Present at TD Cowen's 45th Annual Health Care Conference

Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License

ALNY

COEP

REGN

SMMT

VRTX

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Royalty Pharma

Royalty Pharma (NASDAQ:RPRX) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga